Literature DB >> 26086150

Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions.

Thachanan Kongpan1, Surakameth Mahasirimongkol, Parinya Konyoung, Sirimas Kanjanawart, Pansu Chumworathayi, Nuanjun Wichukchinda, Runglak Kidkeukarun, Suphanlinee Preechakul, Usanee Khunarkornsiri, Warawut Bamrungram, Butsaban Supharatwattanakun, Piroon Mootsikapun, Supanida Kwangsukstid, Sukanda Denjanta, Suda Vannaprasaht, Watcharee Rungapiromnan, Wimon Suwankesawong, Wongwiwat Tassaneeyakul, Wichittra Tassaneeyakul.   

Abstract

BACKGROUND: Co-trimoxazole is a sulfonamide-containing antibiotic that is effective in the treatment of several infections and for prophylaxis of Pneumocystis jiroveci pneumonia. This drug has been reported as a common culprit drug for the Stevens-Johnson syndrome (SJS) and for toxic epidermal necrolysis (TEN). Human leukocyte antigens (HLAs) play a key role in the immunopathogenesis of severe cutaneous reactions induced by several drugs. This study investigated the association between the HLA class I and HLA-DRB1 polymorphisms and co-trimoxazole-induced SJS/TEN in a Thai population.
METHODS: Forty-three patients with co-trimoxazole-induced SJS/TEN and 91 co-trimoxazole-tolerant patients were enrolled in the study. HLA class I and HLA-DRB1 were genotyped using the reverse sequence-specific oligonucleotide probe method.
RESULTS: The frequencies of three alleles of HLA, namely HLA-B*15:02, HLA-C*06:02, and HLA-C*08:01, were significantly higher in the co-trimoxazole-induced SJS/TEN group compared with controls. The risks for co-trimoxazole-induced SJS/TEN in patients with the HLA-B*15:02, HLA-C*06:02, or HLA-C*08:01 allele were about 3-11-fold higher when compared with those who did not carry one of these alleles. Individuals who carried the HLA-B*15:02-C*08:01 haplotype had a 14-fold higher risk for co-trimoxazole-induced SJS/TEN.
CONCLUSION: Evidence of associations between co-trimoxazole-induced SJS/TEN and HLA alleles including HLA-B*15:02, HLA-C*06:02, and HLA-C*08:01 were found in the study population. These findings may suggest that apart from the HLA molecules, other molecules involved in the molecular pathogenesis of these severe cutaneous adverse drug reactions may play an important role in the susceptibility of individuals to SJS/TEN caused by co-trimoxazole.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26086150     DOI: 10.1097/FPC.0000000000000153

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  24 in total

Review 1.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

2.  Suspected Case of Drug-Induced Acute Respiratory Distress Syndrome following Trimethoprim-Sulfamethoxazole Treatment.

Authors:  Julia Natterer; Frida Rizzati; Marie-Hélène Perez; David Longchamp; Vivianne Amiet; Quentin DeHalleux; Kim Dao; Thomas Ferry
Journal:  J Pediatr Intensive Care       Date:  2020-07-30

3.  Human Leukocyte Antigen (HLA) Testing in Pharmacogenomics.

Authors:  Ann M Moyer; Manish J Gandhi
Journal:  Methods Mol Biol       Date:  2022

Review 4.  Genetic Basis of Delayed Hypersensitivity Reactions to Drugs in Jewish and Arab Populations.

Authors:  Mohammed Aboukaoud; Shoshana Israel; Chaim Brautbar; Sara Eyal
Journal:  Pharm Res       Date:  2018-09-17       Impact factor: 4.200

5.  Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01.

Authors:  Jirawat Pratoomwun; Paul Thomson; Kanoot Jaruthamsophon; Rawiporn Tiyasirichokchai; Pimonpan Jinda; Ticha Rerkpattanapipat; Wichittra Tassaneeyakul; Nontaya Nakkam; Pawinee Rerknimitr; Jettanong Klaewsongkram; Yuttana Srinoulprasert; Munir Pirmohamed; Dean J Naisbitt; Chonlaphat Sukasem
Journal:  Front Immunol       Date:  2021-04-29       Impact factor: 7.561

6.  HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients.

Authors:  Patompong Satapornpong; Jirawat Pratoomwun; Pawinee Rerknimitr; Jettanong Klaewsongkram; Nontaya Nakkam; Thanyada Rungrotmongkol; Parinya Konyoung; Niwat Saksit; Ajanee Mahakkanukrauh; Warayuwadee Amornpinyo; Usanee Khunarkornsiri; Therdpong Tempark; Kittipong Wantavornprasert; Pimonpan Jinda; Napatrupron Koomdee; Thawinee Jantararoungtong; Ticha Rerkpattanapipat; Chuang-Wei Wang; Dean Naisbitt; Wichittra Tassaneeyakul; Manasalak Ariyachaipanich; Thapana Roonghiranwat; Munir Pirmohamed; Wen-Hung Chung; Chonlaphat Sukasem
Journal:  Front Immunol       Date:  2021-05-04       Impact factor: 7.561

Review 7.  Sulfonamide Drug Allergy.

Authors:  Joshua M Dorn; Mollie Alpern; Caitlin McNulty; Gerald W Volcheck
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-06       Impact factor: 4.919

Review 8.  Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.

Authors:  Rebecca Pavlos; Katie D White; Celestine Wanjalla; Simon A Mallal; Elizabeth J Phillips
Journal:  Immunol Allergy Clin North Am       Date:  2017-11       Impact factor: 3.479

Review 9.  Sulfonamide Hypersensitivity.

Authors:  Timothy G Chow; David A Khan
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-01       Impact factor: 8.667

Review 10.  Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis.

Authors:  Teri A Manolio; Carolyn M Hutter; Mark Avigan; Ricardo Cibotti; Robert L Davis; Joshua C Denny; Lois La Grenade; Lisa M Wheatley; Mary N Carrington; Wasun Chantratita; Wen-Hung Chung; Andrea D Dalton; Shuen-Iu Hung; Ming Ta Michael Lee; J Steven Leeder; Juan J L Lertora; Surakameth Mahasirimongkol; Howard L McLeod; Maja Mockenhaupt; Michael Pacanowski; Elizabeth J Phillips; Simone Pinheiro; Munir Pirmohamed; Cynthia Sung; Wimon Suwankesawong; Lauren Trepanier; Santa J Tumminia; David Veenstra; Rika Yuliwulandari; Neil H Shear
Journal:  Clin Pharmacol Ther       Date:  2017-11-06       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.